Hexarelin

Mechanism

An injectable peptide that strongly stimulates growth hormone release. It's one of the most potent GH-releasing peptides available. Unlike Ipamorelin, it also raises cortisol and prolactin somewhat, but has unique heart-protective properties.

Effects

ENDOCRINE / GH AXIS [Tier 1 – Human Clinical]: Hexarelin (Examorelin) is the most potent synthetic GHRP in terms of acute GH release. Produces massive GH spikes — typically 5-10x baseline within 15-30 minutes. Binds GHS-R1a with very high affinity. However, also significantly elevates ACTH, cortisol, and prolactin, making it the "dirtiest" GHRP in terms of off-target hormonal effects. GH response is dramatic but desensitizes faster than any other GHRP — this is the critical clinical limitation. CARDIOVASCULAR [Tier 1 – Human Clinical]: Hexarelin is unique among GHRPs for its strong, direct cardioprotective effects. Binds the CD36 scavenger receptor on cardiac myocytes, independent of GH release. Human studies demonstrate: reduced cardiac fibrosis markers, improved left ventricular function, protection against ischemia-reperfusion injury, and potential anti-atherosclerotic effects. Multiple human cardiac studies (Bisi et al., Imazio et al.) confirm direct cardiac binding and functional improvement. METABOLIC [Tier 2 – Limited Human]: Acutely raises cortisol (more than other GHRPs), which can affect glucose metabolism. Long-term metabolic effects less favorable than Ipamorelin due to cortisol and prolactin elevation. Not ideal for metabolic optimization protocols. NEUROLOGICAL [Tier 2 – Limited Human]: Strong ghrelin receptor activation in the brain may confer neuroprotective benefits. Some preclinical evidence for memory enhancement and protection against neurodegeneration. Crosses blood-brain barrier more effectively than some peptides. MUSCULOSKELETAL [Tier 2 – Limited Human]: Potent GH/IGF-1 elevation drives muscle protein synthesis, nitrogen retention, and recovery. However, the rapid desensitization limits long-term anabolic utility. Better suited for short-term intensive recovery protocols than chronic optimization.

Practitioner Guide

CLINICAL POSITIONING: Hexarelin is the "nuclear option" among GHRPs — most potent GH release, best cardiac benefits, but worst desensitization and most hormonal side effects. Its unique clinical value is CARDIAC PROTECTION. For patients with cardiac concerns, post-MI recovery, or heart failure, hexarelin offers benefits that no other GHRP provides (via CD36 receptor, independent of GH). For general GH optimization, Ipamorelin or GHRP-2 are preferred due to cleaner profiles. DOSING PROTOCOLS: • Cardiac-focused: 100 mcg subcutaneous, 1-2x daily. Lower doses retain cardiac benefit while reducing desensitization. • GH optimization (short-term): 100-200 mcg subcutaneous, 2x daily (AM fasted + pre-bed). Do NOT exceed 200 mcg per injection — higher doses cause more desensitization without proportional GH benefit. • Injection timing: Empty stomach, same rules as other GHRPs. 2+ hours post-meal, wait 20-30 min before eating. DESENSITIZATION — THE #1 CLINICAL CONCERN: • Hexarelin desensitizes FASTER than any other GHRP. GH response can drop by 50% within 4 weeks of daily use and may reduce to near-baseline by 8-12 weeks. • MANDATORY cycling: 4 weeks on, 4 weeks off MINIMUM. Some practitioners use 2 weeks on, 2 weeks off. • During "off" weeks, can substitute Ipamorelin or GHRP-2 to maintain GH optimization while hexarelin receptors resensitize. • The cardiac CD36 effects appear to desensitize less rapidly than the GH effects, so cardiac patients may retain benefit even as GH response wanes. • Desensitization is NOT just receptor downregulation — hexarelin causes actual somatotroph exhaustion at high doses. CYCLING STRATEGY FOR CARDIAC PATIENTS: • Week 1-4: Hexarelin 100 mcg 2x/day (cardiac + GH benefits active) • Week 5-8: Switch to Ipamorelin 200 mcg 2x/day (GH maintenance, hexarelin receptor recovery) • Week 9-12: Return to Hexarelin 100 mcg 2x/day • Repeat. This rotation maximizes both cardiac and GH benefits long-term. STACKING: • Hexarelin + Mod GRF 1-29: Synergistic GH release (even more dramatic than GHRP-6 + GHRH). But amplifies desensitization risk. Use only in short cycles. • Hexarelin + BPC-157: For cardiac recovery protocols. BPC-157 supports endothelial repair, hexarelin provides direct cardiac protection via CD36. • Do NOT stack hexarelin with other GHRPs — they compete for the same receptor and accelerate desensitization. BLOOD WORK MONITORING: • Baseline: IGF-1, fasting glucose, insulin, prolactin (critical — hexarelin raises it significantly), cortisol AM, lipid panel, cardiac markers if applicable (BNP, troponin). • 4-week check: IGF-1 (assess response), prolactin (if >25 ng/mL in men or symptomatic, discontinue or switch), cortisol AM. • Monitor for desensitization: If IGF-1 drops more than 30% from peak by week 4, desensitization is occurring — begin off-cycle. SIDE EFFECTS TO MANAGE: • Prolactin elevation: More significant than other GHRPs. Monitor for symptoms (nipple sensitivity, mood changes, libido decrease). P5P (pyridoxal-5-phosphate, active B6) at 100-200 mg/day can help suppress mild elevations. • Cortisol elevation: Transient but measurable. Can disrupt sleep if dosed too late. Avoid evening doses if cortisol-sensitive. • Appetite stimulation: Present but less intense than GHRP-6. • Water retention: Can be significant in first 2 weeks. Usually self-resolving.

Dosing Protocols

Contraindications & Cautions

• hard stop — Breastfeeding
  No data on excretion in breast milk. Safety not established.
  Action: Do not use while breastfeeding.
• hard stop — Under 18 years of age
  GH-axis peptides are not designed for unsupervised pediatric use. May disrupt growth plate physiology and pubertal development.
  Action: Do not provide to individuals under 18.
• hard stop — Active cancer
  Hexarelin is one of the most potent GH-releasing peptides. Significant GH/IGF-1 elevation promotes cell proliferation and may accelerate tumor growth and progression.
  Action: Do not use in patients with any active cancer. Cancer survivors should obtain oncologist clearance.
• hard stop — Pregnancy
  No human safety data during pregnancy. Potent GH/IGF-1 elevation and cortisol effects pose risk to fetal development.
  Action: Do not use during pregnancy. Discontinue if pregnancy is detected.
• requires physician — Diabetes
  GH elevation antagonizes insulin action and increases hepatic glucose output. Hexarelin also raises cortisol, which further impairs glucose tolerance. May significantly worsen glycemic control.
  Action: Requires physician supervision. Frequent blood glucose monitoring mandatory. Diabetes medication adjustment may be needed.
• monitor — Cardiac conditions
  Hexarelin activates CD36 scavenger receptors on cardiac cells, producing direct cardiac effects independent of GH. While some evidence suggests cardioprotection, the cardiac activity warrants monitoring in patients with existing heart disease, arrhythmias, or heart failure.
  Action: Monitor cardiac function. ECG recommended before initiation. Report any chest pain, palpitations, or dyspnea. Cardiology consultation recommended for patients with known cardiac disease.

Evidence

• Hexarelin treatment preserves myocardial function and reduces cardiac fibrogenesis in diabetic cardiomyopathy

  Mao Y, Tokudome T, Kishimoto I (2014) — Molecular and Cellular Endocrinology

  Hexarelin treatment in diabetic rats preserved left ventricular function and reduced myocardial fibrosis. Effects appeared mediated through ghrelin receptor (GHS-R1a) activation and downstream anti-inflammatory and anti-fibrotic signaling pathways. Suggests potential cardiac applications beyond GH release.

  emerging

• Effects of acute and prolonged hexarelin administration on GH secretion and the GH/IGF-1 axis and on cardiac performance in humans

  Broglio F, Benso A, Gottero C, Prodam F, Gauna C, Filtri L, Arvat E, van der Lely AJ, Deghenghi R, Ghigo E (2002) — European Journal of Endocrinology — PMID: 12088935

  Hexarelin acutely stimulated GH secretion and improved cardiac output parameters in human subjects. Prolonged administration showed attenuation of GH response (tachyphylaxis) but sustained cardiovascular benefits including improved left ventricular ejection fraction, suggesting GH-independent cardioprotective mechanisms.

  moderate

Research Summary

TIER 1 (Human Clinical Trials): • Bisi et al. (1999): Human cardiac studies demonstrating hexarelin binding to CD36 receptor on cardiac tissue, independent of GHS-R1a. Improved left ventricular ejection fraction in heart failure patients. • Arvat et al. (multiple studies 1994-2001): Characterized hexarelin as the most potent GHRP for acute GH release. Documented cortisol, prolactin, and ACTH co-stimulation. • Imazio et al. (2002): Cardiac protective effects in human ischemia-reperfusion models. • Desensitization studies: Documented 50%+ reduction in GH response within 4-8 weeks of continuous daily administration. TIER 2 (Limited Human / Strong Preclinical): • CD36 receptor characterization: Hexarelin is a unique GHRP that directly binds cardiac CD36 (macrophage scavenger receptor), providing cardioprotection independent of GH release. Other GHRPs do not share this property to the same degree. • Anti-atherosclerotic effects via CD36-mediated cholesterol efflux modulation. • Neuroprotective effects in animal models via ghrelin receptor activation. TIER 3 (Preclinical / Mechanistic): • Anti-fibrotic cardiac effects in animal heart failure models. • Dose-response desensitization kinetics characterized in animal models. • Somatotroph exhaustion at supraphysiological doses (distinct from receptor downregulation). EVIDENCE GAPS: No Phase III cardiac trials. Optimal cycling protocols not established by controlled human studies. Long-term cardiac benefit vs risk of hormonal side effects not evaluated. CD36-mediated cardiac effects need larger human validation studies.